ISSN 0974-763X
UGC-CARE Listed Journal

SOUTH ASIAN JOURNAL OF MANAGEMENT RESEARCH (SAJMR)

Volume 15, Issue No.1 January, 2025

CHHATRAPATI SHAHU INSTITUTE OF BUSINESS EDUCATION AND RESEARCH (CSIBER), KOLHAPUR, MAHARASHTRA, INDIA

(An Autonomous Institute)
University Road, Kolhapur - 416004, Maharashtra State, India.

website : www.siberindia.edu.in
E-mail : editorsajmr@siberindia.edu.in

Chhatrapati Shahu Institute of Business Education and Research (CSIBER)

South Asian Journal of Management Research (SAJMR)

Volume 15, Issue No. 1, January, 2025

Editor: Dr. Pooja M. Patil

Publisher

CSIBER Press

Central Library

Chhatrapati Shahu Institute of
Business Education & Research (CSIBER)
University Road, Kolhapur – 416004, Maharashtra, India.
Phone: 91-231-2535706/07, Fax: 91-231-2535708,
Website: www.siberindia.edu.in
Email: csiberpress@siberindia.edu.in
Editor Email: editorsajmr@siberindia.edu.in

Address:
CSIBER Press
Central Library Building
Chhatrapati Shahu Institute of Business Education and Research (CSIBER),
University Road Kolhapur, Maharashtra - 416004, India.

ISSN: 0974-763X

Price: INR ₹ 1,200/-

Editor: Dr. Pooja M. Patil

Distributed By

CSIBER Press

Central Library

Chhatrapati Shahu Institute of
Business Education & Research (CSIBER)
University Road, Kolhapur – 416004, Maharashtra, India.
Phone: 91-231-2535706/07, Fax: 91-231-2535708,
Website: www.siberindia.edu.in
Email: csiberpress@siberindia.edu.in

Advances in Cancer Cell Research: Managing and Bridging Molecular Insights, Epigenetic Innovations, Artificial Intelligence, and Clinical Applications to Shape the Future of Precision Oncology and Sustainable Therapeutics

Siddharth Rath
sidbat1596@gmail.com
Ph. D. Research Scholar
Department of Chemical Engineering
Indian Institute of Technology, Bombay IIT – B, India

Abstract
Cancer research has made remarkable strides in the past few decades, driven by innovations in precision medicine, immunotherapy, and advanced diagnostic tools. This paper provides an in-depth exploration of these advancements, focusing on the integration of molecular biology, artificial intelligence (AI), and sustainable practices in oncology. The study begins by examining the shift from traditional therapies, such as chemotherapy and radical surgeries, to targeted approaches like EGFR inhibitors, BCR-ABL inhibitors, and VEGF inhibitors. It highlights their success in improving patient outcomes while addressing the challenges posed by tumour heterogeneity and acquired resistance. The role of the tumour microenvironment (TME) and cancer stem cells (CSCs) in therapy resistance and recurrence is critically analysed, with insights into novel approaches targeting these components. Strategies like CAR-T cell therapies, immune checkpoint inhibitors, and combination immunotherapies underscore the importance of leveraging the immune system to combat cancer effectively. Advances in epigenetic therapies, such as histone deacetylase inhibitors and DNA methyltransferase inhibitors, showcase how gene expression modulation offers new hope for previously untreatable malignancies.

Delving into the transformative role of AI and machine learning in cancer diagnosis, prognosis, and drug discovery, and analysing large datasets, AI-driven models improve early detection, predict treatment responses, and accelerate the development of novel therapeutics. Additionally, liquid biopsies, a non-invasive diagnostic tool, are emphasized for their potential in real-time monitoring of disease progression and resistance mutations. To ensure sustainability, the study discusses the need for equitable access to these advanced therapies, particularly in low-resource settings. Emphasis is placed on scalable solutions such as telemedicine, mobile radiotherapy units, and global collaborations to bridge the gap in healthcare disparities. Finally, the integration of multi-omics data, combined with AI and innovative therapeutic strategies, is presented as a pathway to a more personalized and effective oncology paradigm. This paper not only addresses the scientific advancements reshaping cancer treatment but also highlights the importance of sustainability in research and healthcare delivery. By adopting innovative and inclusive strategies, the global oncology community can better combat cancer while ensuring equitable outcomes for all.

Keywords: Precision Medicine, Tumour Microenvironment (TME), Cancer Stem Cells (CSCs), Immunotherapy, Liquid Biopsy, Epigenetic Therapies, Targeted Therapies, Sustainable Healthcare, Multi-Omics Integration, Combination Therapy, Resistance Mechanisms, Oncology Innovations

Introduction

Historical Context of Cancer Treatments

The history of cancer treatment mirrors humanity's evolving scientific understanding. In the Edwin Smith Papyrus (~1700 BC), tumors were described as incurable, reflecting the rudimentary knowledge of the era. Early therapeutic interventions, rooted in the humoral theory of Hippocrates, attempted to restore bodily fluid balance through practices like bloodletting and cupping.

The advent of modern surgery in the 19th century marked a pivotal shift. William Halsted's **radical mastectomy**, premised on the theory of centrifugal cancer spread, demonstrated early success in local recurrence reduction, with recurrence rates falling to **6% locally** and **14% regionally**. Despite its efficacy in localized control, systemic failures became evident, with many patients succumbing to distant metastases. This underscored the need for integrated systemic and local treatment approaches.

Paradigm Shift: Systemic Disease Theories

In the mid-20th century, Bernard Fisher revolutionized cancer biology by positing that cancer is systemic from its inception. According to Fisher's theory, metastasis occurs early via the bloodstream, rendering extensive local surgeries insufficient. Randomized trials subsequently demonstrated that **lumpectomy combined with**

radiotherapy offered survival outcomes comparable to those of radical mastectomy, paving the way for more conservative surgical techniques.

Innovative Modalities in Cancer Treatment

Targeted Intra-Operative Radiotherapy (TARGIT): A Case Study in Precision
TARGIT epitomizes the evolution of cancer treatment toward precision medicine. This technique delivers a focused radiation dose directly to the tumor bed intra-operatively, sparing healthy tissues and obviating the need for prolonged post-operative radiotherapy.

Dosimetric Principles

Radiation dose effectiveness in TARGIT is quantified using the **Linear Quadratic Model**:

$E=nD(1+D/(\alpha/\beta))$

Where:

- E: Biological effect of radiation.
- n: Number of fractions.
- D: Dose per fraction.
- α/β: Ratio reflecting tissue radiosensitivity (10 Gy for tumors, 3 Gy for normal tissues).

Pilot Study Results

A TARGIT pilot study involving **26 patients** aged **30–80 years** yielded compelling results:

- **Local recurrence**: 0% over a **34-month** median follow-up.
- **Treatment time**: Reduced to **30 minutes** compared to conventional **6-week** regimens.
- **Patient satisfaction**: Rated at **95%**, attributed to reduced treatment burden and superior cosmetic outcomes.

Radiotherapy beyond TARGIT: Addressing Multicentricity
Multicentricity, characterized by the presence of multiple tumor foci within a single organ, presents a significant challenge in breast cancer treatment. Whole-organ analyses reveal that up to **63%** of mastectomy specimens harbor occult foci, though most are confined to within **2–4 cm** of the primary tumor.

TARGIT's Role
TARGIT addresses this challenge by delivering a concentrated dose to the tumor bed, effectively neutralizing residual malignant cells while avoiding unnecessary irradiation of distant foci.

Clinical Trial Insights
The Oxford Overview meta-analysis consolidated data from multiple trials, reinforcing that **localized recurrence rates** could be significantly reduced through targeted radiotherapy, with no impact on overall survival.

Methodical approach to Insights in Cancer Research data sampling and analysis and

Molecular Insights in Cancer Research

DNA Fingerprinting: Ensuring Research Integrity
The authenticity of cell lines is paramount in cancer research. Contamination and misidentification, affecting **18%** of research cell lines globally, compromise experimental reproducibility and validity. DNA fingerprinting provides a robust solution through high-resolution analysis of genetic polymorphisms.

Methodologies: VNTR and STR Analysis

- **VNTR (Variable Number Tandem Repeats)**: Exploits minisatellite regions for differentiation based on allele length.
- **STR (Short Tandem Repeats)**: Microsatellite markers, characterized by short, repeating sequences, enable precise genetic profiling.

Technical Application

Amplified Fragment Length Polymorphism (AmpFLP):

- DNA regions are amplified via Polymerase Chain Reaction (PCR).
- Electrophoresis segregates DNA fragments by size.
- Resulting profiles are matched against reference databases for verification.

Statistical Modelling and Data Analysis

Optimizing Radiation Therapy with Mathematical Models
Radiation dose optimization is essential in achieving therapeutic efficacy while minimizing side effects. The dosimetric profile of radiotherapy, particularly in TARGIT, is governed by dose distribution models.

Exponential Dose Attenuation Model

The following model predicts dose attenuation based on tissue depth:

D(x) = D0e^{-kx}

Where:

- D(x): Radiation dose at depth xx.
- D0D_0: Surface dose.
- k: Attenuation constant (dependent on tissue properties).

For TARGIT, the surface dose (D0) is typically **20 Gy**, attenuating to a therapeutic dose of **5 Gy** at **1 cm** depth.

Clinical Trial Data Insights

Meta-analyses play a pivotal role in synthesizing large-scale data. The **Oxford Overview**, analyzing trials across decades, confirmed equivalence in survival between conservative and radical surgeries, provided radiotherapy accompanies lumpectomy.

Summary of Results

Parameter	Lumpectomy + Radiotherapy	Radical Mastectomy
5-Year Survival (%)	87	86
Local Recurrence Rate (%)	10	6
Cosmetic Satisfaction (%)	92	40

The reduction in recurrence rates with radiotherapy underscores its adjunctive value, while superior cosmetic outcomes favor conservative approaches.

Predictive Modeling in Treatment Outcomes

Mathematical models assist in predicting recurrence risks and optimizing therapy protocols. A commonly used predictive model incorporates tumor doubling time (Td) and treatment delay (Tdelay):

$$R_{rec} = R_0 e^{\lambda T_{delay}}$$

Where:

- Rrec: Recurrence risk.
- R0: Baseline recurrence probability.
- λ: Growth constant related to Td.

Application:

For a tumor with Td=60 = 60 days and Tdelay=30T_{delay} = 30 days:

$$\lambda = \ln(2)/T_d = 0.0116\,\text{per day}$$

$$R_{rec} = R_0 e^{0.0116 \cdot 30} \approx R_0 \cdot 1.39$$

This calculation demonstrates how delays in treatment amplify recurrence risks, reinforcing the need for timely interventions.

Challenges in Treatment Personalization

Tumour Heterogeneity and Genomic Insights

Tumour heterogeneity poses a formidable challenge to treatment uniformity. Advances in next-generation sequencing (NGS) reveal significant inter- and intra-tumoral genetic variability, necessitating personalized therapies.

Key Findings from Genomic Profiling:

- **BRCA Mutations**: Strong predictors of response to PARP inhibitors.
- **HER2 Overexpression**: Linked to improved outcomes with targeted monoclonal antibodies like trastuzumab.

Personalized treatment frameworks integrate these markers to tailor therapeutic strategies, enhancing efficacy.

Addressing Disparities in Access to Care

Geographical and socioeconomic barriers hinder equitable access to advanced treatments like TARGIT. Strategies to mitigate these disparities include:

- Establishing **mobile radiotherapy units** for rural regions.
- Leveraging **telemedicine platforms** to deliver patient follow-ups and education.

Technological Innovations in Cancer Research

Artificial Intelligence in Oncology

Artificial Intelligence is revolutionizing cancer diagnostics and treatment planning. Algorithms trained on imaging data identify tumor boundaries with unprecedented accuracy, guiding precision surgeries.

AI Applications:

- **Radiomics**: Extracting quantitative features from imaging data to predict treatment outcomes.
- **Predictive Analytics**: Forecasting patient responses to chemotherapy based on historical datasets.

Advancements in Imaging Modalities

Modern imaging techniques enhance tumor visualization, aiding in diagnosis and intra-operative decision-making.

Comparative Analysis of Imaging Modalities:

Modality	Sensitivity (%)	Applications
MRI	95	Detecting multicentricity
PET-CT	90	Identifying metastases
Mammography	85	Screening for early lesions

Integration of Molecular Diagnostics

Techniques like liquid biopsies are gaining traction for their minimally invasive nature. These tests detect circulating tumor DNA (ctDNA) and exosomes, providing real-time insights into tumor dynamics.

Data Integration for Comprehensive Care
Combining clinical, genomic, and imaging data within unified platforms facilitates precision oncology. AI-driven analytics synthesize these datasets, offering holistic patient management.

The integration of molecular diagnostics, personalized therapies, and AI-driven tools heralds a new era in cancer care. Future research priorities include:

- Expanding TARGIT's application beyond breast cancer to other solid tumors.
- Developing biomarkers for predicting treatment resistance.
- Establishing global collaborations for equitable access to advanced technologies.

The Role of Local Therapies in Cancer Management
Local therapies, including surgery and radiotherapy, are critical in controlling tumor growth at the primary site. While radical approaches dominated early cancer treatment, modern strategies emphasize precision and minimal invasiveness.

Comparative Effectiveness of Local Therapies:

Therapy Type	Primary Outcome	Associated Challenges
Radical Surgery	High local control	Increased morbidity, scarring
Conservative Surgery	Comparable survival rates	Risk of residual disease
Radiotherapy (TARGIT)	Reduced treatment time, improved cosmetic outcomes	Accessibility in remote areas

Conservative approaches like TARGIT combine precision with efficacy, representing a paradigm shift in localized cancer care.

Systemic Therapy Innovations
Systemic therapies address metastases and microscopic disease beyond the primary site. Developments in chemotherapy, immunotherapy, and targeted treatments have significantly improved survival rates.

Immunotherapy: Revolutionizing Cancer Treatment
Immune checkpoint inhibitors (e.g., pembrolizumab) unleash the immune system's potential by targeting molecules like PD-1 and CTLA-4.

Mechanism of Action:
Checkpoint inhibitors block suppressive signals within T cells, enabling an amplified immune response against tumor cells. This approach has demonstrated exceptional efficacy in malignancies like melanoma and lung cancer.

Limitations:
Despite promising outcomes, challenges include immune-related adverse events (irAEs) and variable patient responses, often driven by tumor mutational burden and the immune microenvironment.

Synergistic Approaches: Combining Local and Systemic Therapies
The integration of local and systemic treatments offers a comprehensive strategy for cancer care. Examples include:

- **Neoadjuvant Therapy**: Systemic treatments administered pre-operatively to shrink tumors, facilitating conservative surgeries.
- **Adjuvant Radiotherapy**: Delivered post-surgery to eradicate microscopic disease, enhancing long-term control.

Molecular and Cellular Advances

Role of Tumour Microenvironment in Therapy Resistance
The tumour microenvironment (TME) comprises cellular and extracellular components that influence treatment outcomes. Hypoxic conditions within the TME, for instance, reduce radiotherapy efficacy by impairing reactive oxygen species (ROS) generation.

Emerging Solutions:

- **Hypoxia-Activated Prodrugs**: Selectively target hypoxic tumor cells.
- **Oxygen Delivery Systems**: Enhance radiotherapy efficacy by normalizing TME oxygenation.

Role of Cancer Stem Cells (CSCs)
CSCs are a subpopulation within tumors capable of self-renewal and driving recurrence. Their inherent resistance to conventional therapies necessitates innovative targeting strategies.

Potential Approaches:

- **Wnt/Beta-Catenin Inhibitors**: Block critical CSC signaling pathways.
- **Nanoparticle-Based Delivery**: Enhances the specificity and bioavailability of CSC-directed agents.

Clinical Trial Frameworks and Ethical Considerations

The Importance of Adaptive Clinical Trials
Traditional clinical trial designs often fail to address the dynamic nature of cancer progression and treatment responses. Adaptive designs, in contrast, allow modifications to trial protocols based on interim results, optimizing patient outcomes.

Features of Adaptive Trials:

- Real-time data integration for treatment adjustments.
- Enhanced efficiency by identifying effective therapies earlier.
- Reduction in patient exposure to ineffective treatments.

Example: I-SPY 2 Trial

The I-SPY 2 trial for breast cancer dynamically assigns patients to therapies based on predictive biomarkers, accelerating the identification of successful combinations.

Mathematical and Computational Models in Oncology

Modeling Tumor Growth Dynamics
Mathematical models provide quantitative frameworks to simulate tumor growth and treatment responses.

Gompertzian Growth Model:
This model describes tumor growth as initially exponential, followed by saturation due to resource constraints:

$$V(t) = V_0 e^{\frac{A}{B}(1-e^{-Bt})}$$

Where:

- V(t): Tumor volume at time tt.
- V0: Initial tumor volume.
- A,B: Growth parameters influenced by tumor biology.

Application:
Predicting tumor shrinkage following chemotherapy to optimize dosing schedules.

Computational Simulations in Radiotherapy Planning
Advanced simulations incorporate imaging data to personalize radiotherapy. Monte Carlo methods, for instance, model radiation transport and dose deposition with high precision.

Case Study: Monte Carlo Simulation for Lung Cancer

- Inputs: Patient-specific CT scans, tumor boundaries, and tissue density maps.
- Outputs: Optimized dose distributions minimizing collateral damage to healthy tissues.

Use of neural networking models and AI accelerate drug development by identifying potential compounds and predicting their biological activity. Deep learning algorithms analyze large datasets, uncovering patterns undetectable by traditional methods, e.g. AlphaFold's protein structure predictions enhance the design of targeted therapies by elucidating drug-target interactions.

The convergence of molecular biology, computational tools, and clinical innovation heralds a transformative era in cancer care. Key directions include:

Integrating Multi-Omic Data: Unifying genomic, proteomic, and metabolomic insights for holistic understanding.

Expanding Accessibility: Bridging gaps in healthcare equity through technological and policy reforms.

Advancing AI Applications: From real-time treatment adjustments to predictive analytics, AI will redefine precision oncology.

Advanced Treatment Modalities: Personalized and Combination Therapies

Personalized Oncology
The era of precision medicine is rooted in understanding patient-specific tumor biology. Tailored therapies target genetic mutations, expression profiles, and epigenetic markers unique to an individual's cancer.

Genomic Profiling and Targeted Therapies
Large-scale sequencing projects, such as The Cancer Genome Atlas (TCGA), have identified actionable mutations in key oncogenes and tumor suppressors (e.g., KRAS, EGFR). These findings have spurred the development of molecularly targeted agents, such as:

- **EGFR Inhibitors**: Gefitinib for EGFR-mutant non-small cell lung cancer (NSCLC).
- **BRAF Inhibitors**: Dabrafenib for BRAF V600E-mutant melanoma.

Pharmacogenomics: Enhancing Efficacy and Reducing Toxicity
By incorporating patient-specific genomic data, pharmacogenomics identifies optimal drug regimens, minimizing adverse effects while maximizing efficacy.

Combination Therapies
Cancer's inherent heterogeneity often necessitates multi-modal treatment approaches. Combination therapies leverage synergies between modalities to overcome resistance mechanisms.

Case Study: Triple-Negative Breast Cancer (TNBC)
TNBC, characterized by the absence of ER, PR, and HER2, poses therapeutic challenges due to its aggressive nature. Combination approaches include:

- **Chemotherapy + Immunotherapy**: The IMpassion130 trial showed that adding atezolizumab (an anti-PD-L1 antibody) to nab-paclitaxel improved progression-free survival in metastatic TNBC.
- **PARP Inhibitors + Chemotherapy**: Synergistic efficacy in BRCA-mutated TNBC.

Mathematical Modeling for Optimal Synergy
The Bliss Independence Model predicts the additive or synergistic effects of combination therapies:

$$E_{combo} = E_A + E_B - (E_A \cdot E_B)$$

Where:

- E_A, E_B: Efficacy of individual agents.
- E_{combo}: Combined efficacy.

Exploring the Immune Landscape

Tumor Immunoediting and Escape Mechanisms
Tumor progression involves immune system interactions, described by the "immunoediting" framework:

- **Elimination**: Immune system detects and eradicates transformed cells.
- **Equilibrium**: Dormant cancer cells persist in a controlled state.
- **Escape**: Tumors evade immune surveillance through mechanisms like PD-L1 overexpression or recruitment of suppressive cells (e.g., Tregs).

Emerging Immune-Based Interventions

- **Chimeric Antigen Receptor (CAR) T-Cells**: Engineered T-cells that recognize specific tumor antigens (e.g., CD19 for B-cell malignancies).
- **Neoantigen Vaccines**: Personalized vaccines based on tumor-specific mutations.

The Role of Biomarkers in Immunotherapy
Biomarkers predict patient response and guide immunotherapy decisions. Notable examples include:

- **Tumor Mutational Burden (TMB)**: Correlates with checkpoint inhibitor efficacy.
- **Microsatellite Instability (MSI)**: Predicts response to pembrolizumab in colorectal cancer.

Case Study: TMB as a Predictor
High TMB (>10 mutations/Mb) is associated with durable responses to PD-1 blockade. However, low TMB tumors may still respond if they exhibit other immunogenic features, such as neoantigen expression.

Single-Cell Sequencing
Single-cell RNA sequencing (scRNA-seq) provides high-resolution insights into tumor heterogeneity by analyzing individual cells within the tumor microenvironment.

Applications in Oncology:

- Identifying rare cell populations, such as CSCs.
- Mapping cellular trajectories during tumor evolution.
- Predicting resistance mechanisms to therapy.

Such a study of glioblastoma using scRNA-seq revealed distinct subpopulations with differential expression of resistance-associated genes, guiding therapeutic strategy development.

Liquid Biopsies: Non-Invasive Diagnostics
Liquid biopsies analyze circulating tumor DNA (ctDNA), exosomes, and tumor-derived cells in blood samples. These tools enable:

- **Early Detection**: Identifying ctDNA mutations in early-stage cancers.
- **Real-Time Monitoring**: Tracking response to therapy and detecting resistance mutations.

Technical Challenges and Innovations:

- **Sensitivity**: Enhanced by digital droplet PCR (ddPCR) and next-generation sequencing.
- **Standardization**: Developing protocols for ctDNA quantification and analysis.

Advancing the Role of Cancer Immunotherapy

Immune Checkpoint Inhibitors: Expanding Horizons
Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy, targeting immune-suppressive pathways that tumor cells exploit to evade immune detection. PD-1, PD-L1, and CTLA-4 inhibitors are currently the most widely utilized ICIs. Their impact has been profound, especially in cancers like melanoma, NSCLC, and head and neck squamous cell carcinoma (HNSCC).

Mechanism of Action
Immune checkpoint inhibitors prevent the binding of checkpoint proteins (e.g., PD-L1 on tumors to PD-1 on T-cells), which normally dampen immune responses. This blockade enhances the immune system's ability to recognize and destroy tumor cells.

Case Study: PD-1/PD-L1 Inhibition
The **KEYNOTE-001** trial, which evaluated pembrolizumab (anti-PD-1), demonstrated a response rate of **45%** in advanced melanoma, with durable responses seen in many patients. Similar results have been observed in other cancers, but challenges remain in identifying biomarkers for response.

Resistance to ICIs
Resistance to immune checkpoint inhibitors remains a significant issue, often caused by:

- **Low Tumor Mutational Burden (TMB)**: Cancers with fewer mutations may lack the diversity of neoantigens necessary for immune recognition.
- **Immunosuppressive Tumor Microenvironment (TME)**: Tumors may recruit immunosuppressive cells like Tregs and myeloid-derived suppressor cells (MDSCs), which inhibit the action of T-cells.

Overcoming Resistance with Combination Immunotherapy
Combining ICIs with other immunotherapies or treatments holds the potential to overcome resistance. Some promising combinations include:

- **CTLA-4 + PD-1 Inhibition**: The combination of ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) has demonstrated impressive results in metastatic melanoma, with **median overall survival (OS)** extending beyond 5 years in a subset of patients.
- **Chemotherapy + ICIs**: Chemotherapy may act by increasing T-cell priming and enhancing the efficacy of ICIs. Studies have shown that chemotherapy-induced tumor death releases neoantigens, providing additional targets for immune cells.

In **NSCLC**, the combination of **nivolumab** and **chemotherapy** led to significantly improved progression-free survival (PFS) compared to chemotherapy alone, resulting in its FDA approval for first-line treatment in patients without driver mutations.

The Role of Cancer Vaccines

Cancer vaccines are classified into two broad categories:

- **Active Vaccines**: Designed to stimulate the immune system to recognize and attack cancer cells by presenting specific tumor antigens.
- **Passive Vaccines**: Involve the infusion of ready-made antibodies or T-cells to fight cancer.

Example of Active Vaccine:
The **Cervarix** and **Gardasil** vaccines against **HPV** have been highly successful in preventing cervical cancer, showing how prophylactic vaccines can reduce cancer incidence by targeting oncogenic viruses.

Example of Passive Vaccine:
Kymriah, an autologous CAR-T cell therapy for leukemia, represents a significant step in using engineered T-cells as passive cancer vaccines. In the **ELIANA trial**, **83%** of pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) achieved remission with CAR-T cell therapy.

Tumor Antigens and Vaccine Targets
The discovery of **tumor-associated antigens (TAAs)** has paved the way for the development of therapeutic vaccines. These antigens are present in higher quantities or with altered forms in tumor cells compared to normal cells.

Key Tumor Antigens:

- **HER2**: Overexpressed in certain breast cancers, making it a target for trastuzumab (Herceptin) and vaccine-based therapies.
- **Mucin-1 (MUC-1)**: Abnormally expressed in several epithelial cancers, including breast, lung, and ovarian cancers.

Challenges in Vaccine Development
Despite the promise of cancer vaccines, several challenges persist:

- **Tumor Heterogeneity**: Tumors evolve genetically, making it difficult to identify universal antigens.

- **Immune Tolerance**: Tumor cells may suppress immune responses, making it difficult for vaccines to initiate a robust immune response.

Nanotechnology in Cancer Treatment: The Potential of Nanoparticles for Targeted Delivery

Nanotechnology has emerged as a promising field for improving the delivery of chemotherapeutic agents, reducing systemic toxicity, and enhancing tumor specificity. Nanoparticles, with diameters typically in the range of **1-100 nm**, can encapsulate drugs and target them specifically to cancer cells.

Mechanisms of Action
Nanoparticles can be designed to release their payload in response to specific stimuli, such as changes in pH or temperature within the tumor microenvironment. For instance:

- **Liposomes**: Lipid-based nanoparticles that encapsulate chemotherapy agents, such as doxorubicin, and allow for targeted delivery.
- **Gold Nanoparticles**: These have unique optical properties that enable them to be used for both diagnostic imaging and therapy.

Example: Doxil, a liposomal formulation of doxorubicin, has improved outcomes in ovarian cancer and HIV-related Kaposi's sarcoma, with reduced side effects due to targeted delivery.

Diagnostic Nanoparticles: A New Era in Early Detection
Nanoparticles also play a significant role in diagnostics, with functionalized nanoparticles being used in imaging and biosensing. They can be designed to bind specifically to biomarkers found on tumor cells, enabling early detection even before clinical symptoms appear.

Case Study: In **breast cancer**, gold nanoparticles functionalized with **HER2 antibodies** have been used for imaging, helping clinicians to detect **small tumor sizes** that would otherwise be missed by conventional methods like mammography.

Mathematical Models in Cancer Treatment Decision-Making

Models for Predicting Treatment Response
Mathematical models help predict the efficacy of cancer treatments and guide clinical decision-making. These models integrate tumor growth dynamics, therapeutic dosing regimens, and individual patient variables to forecast outcomes.

Gompertzian Growth Model in Therapy Prediction
The Gompertzian model is often used to model tumor growth, especially in solid tumors. It assumes that tumor growth is exponential initially but slows as it approaches a carrying capacity determined by the tumor's interaction with the surrounding environment. The model is expressed as:

$$V(t) = V_0 e^{\frac{A}{B}(1-e^{-Bt})}$$

Where:

- V(t): Tumor volume at time tt.
- V0: Initial tumor volume.
- A, B: Parameters governing the growth rate and carrying capacity.

Application:
This model helps clinicians determine the timing and dosage of chemotherapy required to optimally reduce tumor mass without causing excessive side effects or resistance.

Predicting and Overcoming Drug Resistance
Drug resistance remains a major challenge in cancer therapy, and mathematical models help predict potential pathways of resistance. Models can simulate the tumor's response to targeted therapies, accounting for factors like:

- **Tumor Mutations**: Resistance can emerge from pre-existing mutations or through the acquisition of new mutations.

- **Drug Efflux Pumps**: Some tumors overexpress proteins that pump chemotherapy drugs out of cells, reducing drug efficacy.

Example:
In **ovarian cancer**, mathematical models have been used to predict the emergence of resistance to platinum-based therapies, allowing for early interventions with alternative agents.

Emerging Therapies and Technologies in Cancer

Targeted Therapy: The Next Frontier
Targeted therapies have rapidly transformed the landscape of cancer treatment, particularly in cancers with defined genetic mutations. These therapies act on specific molecular targets associated with cancer, offering more precise treatment options with fewer side effects compared to traditional chemotherapy.

Examples of Targeted Agents:

- **EGFR Inhibitors (e.g., Erlotinib, Gefitinib)**: These inhibitors target the epidermal growth factor receptor (EGFR), which is commonly overexpressed in lung, head and neck, and colorectal cancers.
- **BCR-ABL Inhibitors (e.g., Imatinib)**: This class of drugs targets the BCR-ABL fusion protein, a hallmark of chronic myelogenous leukemia (CML).
- **VEGF Inhibitors (e.g., Bevacizumab)**: Anti-vascular endothelial growth factor (VEGF) therapies block the formation of new blood vessels (angiogenesis) in tumors, starving the cancer of nutrients and oxygen.

Mechanisms of Action
Targeted therapies are designed to interfere with specific molecules involved in cancer cell growth. These therapies can block the activity of overactive oncogenes, inhibit tumor angiogenesis, or repair abnormal DNA in tumor cells.

Overcoming Challenges in Targeted Therapy
Despite their promising potential, targeted therapies face significant challenges:

- **Acquired Resistance**: Tumors can develop resistance to targeted therapies through mutation or activation of alternative signaling pathways.
- **Tumor Heterogeneity**: Even within a single tumor, different subpopulations of cells may express different genetic mutations, complicating the effectiveness of a single-target drug.
- **Off-Target Effects**: Some targeted therapies may affect non-cancerous cells with similar molecular markers, leading to unintended side effects.

Case Study: Targeting BRAF in Melanoma
BRAF mutations occur in approximately 50% of melanomas and are a key target for therapies like **Vemurafenib** and **Dabrafenib**. However, resistance develops in many cases, either through reactivation of the MAPK pathway or mutations in other genes such as NRAS. In response, combination therapies involving BRAF and MEK inhibitors (e.g., **Cobimetinib**) have been developed to prevent resistance and improve outcomes.

Cancer Metabolism and Therapeutic Targeting

The Role of Cancer Metabolism in Tumor Growth
Cancer cells exhibit altered metabolism, often described as the "Warburg effect," in which cells predominantly generate energy through glycolysis rather than oxidative phosphorylation, even in the presence of oxygen. This shift allows for the rapid proliferation of cancer cells and contributes to the tumor's survival in nutrient-deprived environments.

Key Metabolic Targets:

- **Hexokinase 2 (HK2)**: Involved in the first step of glycolysis, overexpressed in many cancers.
- **Pyruvate Kinase M2 (PKM2)**: A critical enzyme in glycolysis that favors cancer cell proliferation.
- **IDH1/2 Mutations**: These mutations are found in several cancers, including glioma and acute myeloid leukemia (AML), and result in the production of an oncometabolite, 2-hydroxyglutarate, which promotes tumorigenesis.

Targeting these metabolic pathways can deprive cancer cells of the energy they need for growth and survival.

Metabolic Inhibition in Cancer Therapy
Targeting cancer metabolism offers a novel therapeutic approach. Drugs that inhibit key metabolic enzymes have been tested in clinical trials, with varying degrees of success.

Example: Targeting Glycolysis with 3-Bromopyruvate
3-Bromopyruvate (3BP) is a compound that inhibits glycolysis by targeting hexokinase 2. Preclinical studies have shown that 3BP effectively inhibits the growth of several cancers, including liver cancer and colorectal cancer. However, its clinical application has been limited by issues with drug delivery and toxicity.

Example: Inhibiting the IDH1 Mutation
IDH1 inhibitors, such as **AG-120**, have shown promise in treating IDH1-mutated gliomas and AML. These inhibitors work by preventing the conversion of isocitrate to 2-hydroxyglutarate, reducing the oncometabolite's accumulation and thus inhibiting tumor growth.

Gene Therapy and CRISPR in Cancer Treatment

Gene Editing: The Promise of CRISPR-Cas9

The advent of CRISPR-Cas9 technology has revolutionized gene therapy by allowing for precise editing of the genome. This technology enables scientists to target and correct specific mutations that drive cancer development, offering a potential cure for genetically driven cancers.

Applications in Cancer:

- **Gene Correction**: CRISPR can be used to repair mutations in tumor-suppressor genes such as TP53 or PTEN, which are commonly altered in cancer.
- **Immune System Enhancement**: CRISPR has been used to modify T-cells to express chimeric antigen receptors (CAR), creating more potent CAR-T cell therapies for cancers like leukemia and lymphoma.

Case Study: CRISPR in Lung Cancer
In preclinical models, CRISPR has been used to knockout the **EGFR** mutation, a common driver in non-small cell lung cancer (NSCLC), leading to the inhibition of tumor growth and improved survival. Clinical trials for CRISPR-based therapies are still in their infancy but hold promise for targeting genetic drivers of cancer.

Challenges in Gene Therapy for Cancer
Despite the promise of gene therapy and CRISPR, several challenges need to be addressed:

- **Delivery Methods**: Efficient delivery of gene-editing tools to cancer cells remains a significant hurdle. Viral vectors, nanoparticles, and electroporation are among the methods being explored.
- **Off-Target Effects**: The risk of unintended edits, which could cause harmful mutations or activate oncogenes, is a concern for clinical applications.
- **Ethical Considerations**: Gene therapy raises significant ethical issues, particularly regarding germline editing and potential unintended long-term effects.

The Role of Epigenetics in Cancer

Epigenetic Modifications and Cancer
Epigenetics refers to the heritable changes in gene expression that do not involve alterations in the DNA sequence itself. These modifications, such as DNA methylation, histone modification, and non-coding RNA regulation, can significantly influence tumor development, progression, and response to treatment.

Key Epigenetic Mechanisms:

- **DNA Methylation**: Addition of a methyl group to the cytosine residues in CpG islands, often leading to gene silencing. Aberrant hypermethylation of tumor suppressor genes such as **p16INK4a** and **BRCA1** has been observed in various cancers, including lung and breast cancers.
- **Histone Modification**: The addition or removal of chemical groups to histones can alter chromatin structure and gene expression. Modifications such as acetylation and methylation of histones have been shown to either activate or repress transcription.

- **Non-Coding RNAs**: MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) are involved in the regulation of gene expression at the post-transcriptional level. Dysregulated miRNA expression is implicated in the development of many cancers, including gastric, prostate, and breast cancer.

Epigenetic Therapy in Cancer
Given the critical role of epigenetic changes in cancer, targeting these modifications has emerged as a promising therapeutic approach. Epigenetic drugs aim to reverse the aberrant changes in gene expression that contribute to cancer progression.

Examples of Epigenetic Therapies:

- **DNA Methyltransferase Inhibitors**: Drugs such as **5-azacytidine** and **decitabine** inhibit DNA methylation, potentially restoring the expression of tumor suppressor genes in cancers such as myelodysplastic syndromes and acute myeloid leukemia (AML).
- **Histone Deacetylase Inhibitors (HDACi)**: HDAC inhibitors such as **vorinostat** and **romidepsin** aim to prevent the deacetylation of histones, leading to an open chromatin structure and reactivation of tumor suppressor genes. HDAC inhibitors have been used in treating T-cell lymphomas and are being explored in combination therapies for other cancers.
- **BET Inhibitors**: Bromodomain and extra-terminal domain (BET) inhibitors target the interaction between acetylated histones and BET family proteins, which regulate the expression of genes involved in cell growth and survival. These inhibitors have shown promise in hematologic malignancies and solid tumors.

Challenges in Epigenetic Therapy:
Despite promising results, there are several challenges to the widespread use of epigenetic therapies:

- **Tumor Specificity**: Identifying the correct epigenetic targets in different types of tumors remains a challenge.
- **Off-Target Effects**: Epigenetic drugs may affect normal cells, leading to toxicity or side effects.

  Resistance Mechanisms: Cancer cells can develop resistance to epigenetic therapies by altering their epigenetic profiles.

Liquid Biopsy: Revolutionizing Early Cancer Detection

Liquid biopsy is a non-invasive diagnostic tool that analyzes tumor-derived components from bodily fluids, such as blood, urine, or saliva. These components include circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and microRNAs. Liquid biopsy offers a promising alternative to tissue biopsies for cancer diagnosis, monitoring, and prognostication.

Key Advantages of Liquid Biopsy:

- **Non-invasive**: Provides a less invasive alternative to traditional tissue biopsy, which can be painful and difficult to perform repeatedly.
- **Real-Time Monitoring**: Liquid biopsies enable the monitoring of tumor dynamics in real-time, including the detection of mutations or resistance markers as treatment progresses.
- **Early Detection**: Liquid biopsy can potentially detect cancers at an early stage, when the tumor is localized and more treatable, as well as monitor minimal residual disease after treatment.

Clinical Applications of Liquid Biopsy
Liquid biopsy is becoming an invaluable tool in clinical practice, with multiple applications across different stages of cancer care:

Early Detection of Cancer: Liquid biopsy can be used to detect ctDNA or CTCs in early-stage cancers, offering the potential for screening asymptomatic individuals before they develop clinical symptoms. For example, the detection of **EGFR mutations** in lung cancer patients using liquid biopsy can identify the disease at an earlier stage, improving survival outcomes by enabling earlier intervention.

Therapy Monitoring and Prognosis: During cancer treatment, liquid biopsies can track changes in ctDNA levels, providing real-time information on how well a patient is responding to therapy. Rising ctDNA levels may indicate disease progression, even in the absence of clinical symptoms or imaging changes. This enables clinicians to adjust treatments before clinical relapse occurs.

Identification of Resistance Mutations : Liquid biopsy is also used to detect emerging resistance mutations, which can guide treatment decisions. For example, in non-small cell lung cancer (NSCLC), liquid biopsies can identify **EGFR T790M** mutations that confer resistance to first-line EGFR inhibitors, enabling physicians to switch to second-line therapies such as **Osimertinib**.

Case Study: Liquid Biopsy in NSCLC
In a study of **EGFR-mutant NSCLC**, liquid biopsy was used to track **T790M mutations** during the course of treatment with EGFR tyrosine kinase inhibitors (TKIs). The liquid biopsy approach detected T790M mutations in ctDNA before they were identified through imaging or tissue biopsy, allowing for the early introduction of **Osimertinib** and significantly improving patient outcomes.

Challenges and Limitations of Liquid Biopsy

While liquid biopsy holds great promise, several challenges must be addressed before it can be widely adopted:

- **Sensitivity and Specificity**: Liquid biopsy is still less sensitive than traditional tissue biopsies, particularly in early-stage cancers or low-burden tumors. Detecting ctDNA or CTCs at low levels requires highly sensitive assays.
- **Standardization**: There is a lack of standardized protocols for liquid biopsy collection, processing, and analysis, which can lead to variability in results.
- **Regulatory Approval**: As a relatively new technology, liquid biopsy assays are still undergoing regulatory review, and the process for establishing clinical validity and utility is ongoing.

Shaping the Future of Cancer Treatment: A New Horizon

Artificial Intelligence and Machine Learning in Cancer Research

AI and Machine Learning in Early Diagnosis
Artificial intelligence (AI) and machine learning (ML) are rapidly transforming cancer diagnostics by providing tools for early detection, improving accuracy, and aiding in treatment decisions. AI algorithms are increasingly being used to analyze medical imaging, genomic data, and patient records, offering enhanced diagnostic capabilities.

Applications in Imaging:
AI-powered tools for radiology and pathology can automatically analyze medical images (such as CT scans, MRIs, and X-rays) and detect subtle patterns that may be overlooked by human experts. These tools use deep learning, a subset of machine learning, to recognize complex patterns in data. For example, deep convolutional neural networks (CNNs) are being used to identify features associated with lung cancer, breast cancer, and other malignancies in medical images.

Case Study: AI in Breast Cancer Detection: A recent study demonstrated that an AI model trained on mammogram images achieved a breast cancer detection accuracy of 94%, surpassing human radiologists. The model also reduced false positives, which often lead to unnecessary biopsies and patient anxiety.

AI in Personalized Treatment and Drug Development
AI and ML also play a significant role in **personalized cancer treatment** by predicting how patients will respond to specific therapies based on their genetic and molecular profiles.

Applications:

- **Predicting Drug Response**: AI algorithms can analyze large datasets, including genomic and proteomic data, to predict how different patients will respond to various cancer therapies. For example, **IBM Watson for Oncology** uses AI to analyze clinical trial data and patient records to recommend the most appropriate treatment based on the patient's tumor characteristics.
- **Drug Discovery**: AI can accelerate the identification of potential drug candidates by analyzing vast chemical libraries and predicting which compounds are most likely to be effective against specific cancer types. ML algorithms are used to predict the binding affinity of molecules to target proteins, speeding up the drug discovery process.

Case Study: AI in Drug Repurposing: In the fight against COVID-19, AI-based drug repurposing efforts led to the identification of **baricitinib** as a potential treatment. Similarly, AI is being used to identify existing drugs that could be repurposed for cancer therapy, reducing the time and cost of drug development.

Therapeutic Cancer Vaccines
While preventive vaccines like those for HPV and hepatitis B have proven effective in reducing cancer incidence, **therapeutic cancer vaccines** aim to treat existing cancer by stimulating the immune system to attack tumor cells.

Key Approaches:

- **Peptide Vaccines**: These vaccines involve the injection of synthetic peptides derived from tumor-specific antigens. The immune system recognizes these peptides as foreign and mounts a targeted immune response.
- **Dendritic Cell Vaccines**: These vaccines use a patient's dendritic cells (which are key in antigen presentation) to prime the immune system against specific tumor antigens. Dendritic cells are isolated from the patient's blood, exposed to tumor antigens, and then re-infused into the patient.
- **DNA/RNA Vaccines**: These vaccines deliver the genetic material encoding a tumor antigen directly into the patient's cells, which then produce the antigen and stimulate an immune response.

Such as, Sipuleucel-T is an FDA-approved **dendritic cell vaccine** for metastatic prostate cancer. It has demonstrated modest improvements in survival and represents one of the first approved cancer vaccines for therapeutic use.

Challenges and Future Directions in Cancer Vaccine Development
Despite promising advances, the development of effective therapeutic cancer vaccines has faced several hurdles:

- **Tumor Antigen Heterogeneity**: The presence of diverse antigens in different tumor cells complicates the development of a universal vaccine.
- **Immunosuppressive Tumor Microenvironment**: The tumor microenvironment is often hostile to immune responses, with immune checkpoint pathways such as PD-1 and CTLA-4 preventing the immune system from mounting an effective attack.
- **Long-Term Immunity**: Achieving long-term immunity with cancer vaccines remains a challenge, as the immune system can sometimes fail to maintain a response after the initial treatment.

Future efforts will focus on overcoming these barriers by developing combination therapies that integrate vaccines with immune checkpoint inhibitors and other immune-modulatory agents.

The landscape of cancer treatment has evolved significantly, from traditional approaches like surgery and chemotherapy to personalized therapies, immunotherapies, and gene-editing techniques. With the advancement of technologies such as artificial intelligence, liquid biopsy, and CRISPR, we are entering a new era in which cancer can be managed with increasing precision and efficacy.

Key challenges remain, including overcoming drug resistance, improving patient access to cutting-edge treatments, and addressing the complexity of tumor heterogeneity. However, with continued research, collaboration, and the integration of emerging technologies, the fight against cancer will only become more robust.

The future of cancer treatment lies in the seamless integration of targeted therapies, immunotherapy, personalized medicine, and technological innovations to ensure that all patients, regardless of their cancer type, receive the most effective and tailored treatments. As we continue to unlock the mysteries of cancer biology, we move closer to a world where cancer is no longer an insurmountable challenge but a treatable and, ultimately, curable disease.

Appendix 1: Graphs representing data from section 2-5













References

Allison, J.P., 2015. Immune checkpoint blockade in cancer therapy: New insights and opportunities. *Nature Reviews Immunology*, 15(11), pp.635-647.

Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J. and Clarke, M.F., 2003. Prospective identification of tumorigenic breast cancer cells. *Proceedings of the National Academy of Sciences*, 100(7), pp.3983-3988.

American Cancer Society, 2023. Cancer Facts & Statistics Available at: https://www.cancer.org/research.html [Accessed 5 Dec. 2022].

Baer, C., Claus, R. and Plass, C., 2013. Genome-wide epigenetic regulation of miRNAs in cancer. *Cancer Research*, 73(2), pp.473-477.

Barata, P., Sood, A.K. and Hong, D.S., 2019. RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. *Cancer Treatment Reviews*, 74, pp.120-134.

Bardelli, A. and Pantel, K., 2017. Liquid biopsies, what we do not know (yet). *Cancer Cell*, 31(2), pp.172-179.

Beane, J., Spira, A., Lenburg, M., 2017. The emerging role of non-coding RNA in lung cancer. *Lung Cancer Journal*, 113, pp.111-116.

Braun, D.A., Burke, K.P. and Van Allen, E.M., 2016. Genomic markers of checkpoint inhibitor response. *Cancer Cell*, 30(4), pp.577-590.

Brown, J.M. and Wilson, W.R., 2004. Exploiting tumour hypoxia in cancer treatment. *Nature Reviews Cancer*, 4(6), pp.437-447.

Chen, D.S. and Mellman, I., 2017. Elements of cancer immunity and the cancer–immune set point. *Nature*, 541(7637), pp.321-330.

Clevers, H., 2011. The cancer stem cell: premises, promises, and challenges. *Nature Medicine*, 17(3), pp.313-319.

Cristofanilli, M., Budd, G.T., Ellis, M.J., Stopeck, A., Matera, J., Miller, M.C., Reuben, J.M., Doyle, G.V., Allard, W.J., Terstappen, L.W. and Hayes, D.F., 2004. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. *New England Journal of Medicine*, 351(8), pp.781-791.

Croce, C.M., 2009. Causes and consequences of microRNA dysregulation in cancer. *Nature Reviews Genetics*, 10(10), pp.704-714.

Dang, C.V., 2012. MYC on the path to cancer. *Cell*, 149(1), pp.22-35.

Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M.J., Bottomley, W. and Davis, N., 2002. Mutations of the BRAF gene in human cancer. *Nature*, 417(6892), pp.949-954.

Farkona, S., Diamandis, E.P. and Blasutig, I.M., 2016. Cancer immunotherapy: the beginning of the end of cancer?. *BMC Medicine*, 14(1), pp.1-7.

Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D.M., Piñeros, M., Znaor, A. and Bray, F., 2019. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *International Journal of Cancer*, 144(8), pp.1941-1953.

Gatenby, R.A. and Gillies, R.J., 2004. Why do cancers have high aerobic glycolysis?. *Nature Reviews Cancer*, 4(11), pp.891-899.

Gerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P. and Varela, I., 2012. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. *New England Journal of Medicine*, 366(10), pp.883-892.

Hanahan, D. and Weinberg, R.A., 2011. Hallmarks of cancer: the next generation. *Cell*, 144(5), pp.646-674.

Heitzer, E., Haque, I.S., Roberts, C.E. and Speicher, M.R., 2019. Current and future perspectives of liquid biopsies in genomics-driven oncology. *Nature Reviews Genetics*, 20(2), pp.71-88.

International Agency for Research on Cancer, 2020. *World Cancer Report*. Lyon: IARC Press.

Jemal, A., Ward, E., Johnson, C.J., Cronin, K.A., Ma, J., Ryerson, B., Mariotto, A., Lake, A.J., Sherman, R.L., Henley, S.J. and Anderson, R.N., 2017. Annual report to the nation on the status of cancer, 1975–2014, featuring survival. *Journal of the National Cancer Institute*, 109(9).

Jones, P.A. and Baylin, S.B., 2007. The epigenomics of cancer. *Cell*, 128(4), pp.683-692.

Kaelin Jr, W.G., 2005. The concept of synthetic lethality in the context of anticancer therapy. *Nature Reviews Cancer*, 5(9), pp.689-698.

Kamb, A., Wee, S. and Lengauer, C., 2007. Why is cancer drug discovery so difficult?. *Nature Reviews Drug Discovery*, 6(2), pp.115-120.

Karachaliou, N., Rosell, R., Viteri, S. and Rodriguez, S., 2017. Impact of EGFR-TKI resistance mechanisms on the benefit from immunotherapy in lung cancer. *Translational Lung Cancer Research*, 6(1), pp.25-29.

Kim, J.W. and Dang, C.V., 2006. Cancer's molecular sweet tooth and the Warburg effect. *Cancer Research*, 66(18), pp.8927-8930.

Liao, J.B., 2006. Viruses and human cancer. *Yale Journal of Biology and Medicine*, 79(3-4), pp.115-122.

Lu, J., Getz, G., Miska, E.A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B.L., Mak, R.H., Ferrando, A.A. and Downing, J.R., 2005. MicroRNA expression profiles classify human cancers. *Nature*, 435(7043), pp.834-838.

Ma, Q., Long, W., Xing, C., Chu, J., Luo, M. and Wang, H.Y., 2020. Cancer stem cells and immune microenvironment: interplay and therapeutic implications. *Clinical Cancer Research*, 26(5), pp.1071-1081.

McGranahan, N. and Swanton, C., 2017. Clonal heterogeneity and tumor evolution: past, present, and the future. *Cell*, 168(4), pp.613-628.

National Cancer Institute, 2023. What Is Cancer?. Available at: https://www.cancer.gov/about-cancer/understanding/what-is-cancer [Accessed 05 Mar. 2022].

O'Sullivan, D. and Pearce, E.L., 2015. Targeting T cell metabolism for therapy. *Trends in Immunology*, 36(2), pp.71-80.

Pardoll, D.M., 2012. The blockade of immune checkpoints in cancer immunotherapy. *Nature Reviews Cancer*, 12(4), pp.252-264.

Rabinovich, G.A., Gabrilovich, D. and Sotomayor, E.M., 2007. Immunosuppressive strategies that are mediated by tumor cells. *Annual Review of Immunology*, 25, pp.267-296.

Sadelain, M., Brentjens, R. and Rivière, I., 2013. The basic principles of chimeric antigen receptor (CAR) design. *Nature Reviews Cancer*, 13(6), pp.387-398.

Siegel, R.L., Miller, K.D. and Jemal, A., 2020. Cancer statistics, 2020. *CA: A Cancer Journal for Clinicians*, 70(1), pp.7-30.

Stratton, M.R., Campbell, P.J. and Futreal, P.A., 2009. The cancer genome. *Nature*, 458(7239), pp.719-724.

Vogelstein, B. and Kinzler, K.W., 2004. Cancer genes and the pathways they control. *Nature Medicine*, 10(8), pp.789-799.

Wang, Z., Tang, C., Tang, N. and Du, R., 2021. Epigenetics in the age of cancer immunotherapy: mechanisms and applications. *Nature Reviews Genetics*, 22(5), pp.321-333.

Weinberg, R.A., 2013. *The Biology of Cancer*. 2nd ed. New York: Garland Science.

Wicha, M.S., Liu, S. and Dontu, G., 2006. Cancer stem cells: an old idea—a paradigm shift. *Cancer Research*, 66(4), pp.1883-1890.

World Health Organization, 2020. Cancer Fact Sheet. Available at: https://www.who.int/news-room/fact-sheets/detail/cancer [Accessed 15 Mar. 2022].

Wu, T. and Dai, Y., 2017. Tumor microenvironment and therapeutic response. *Cancer Letters*, 387, pp.61-68.

Zhang, J., Yang, P.L. and Gray, N.S., 2009. Targeting cancer with small molecule kinase inhibitors. *Nature Reviews Cancer*, 9(1), pp.28-39.

Zhou, B.B.S. and Elledge, S.J., 2000. The DNA damage response: putting checkpoints in perspective. *Nature*, 408(6811), pp.433-439.

Zou, W., Wolchok, J.D. and Chen, L., 2016. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy. *Nature Reviews Immunology*, 16(3), pp.172-182.

Zhu, H., Luo, H., Yan, M., Zeng, L., Fu, Y., Yang, W. and Zhang, Z., 2018. Epigenetic regulation on gene expression in cancers: Promising drug targets. *Signal Transduction and Targeted Therapy*, 3(1), pp.1-14.

Zoller, M., 2009. Tetraspanins: push and pull in suppressing and promoting metastasis. *Nature Reviews Cancer*, 9(1), pp.40-55.